PARP inhibitors: Significant progress in cancer therapy;Inhibiteurs de la PARP: Des avancées significatives dans le traitement des cancers

Bulletin du Cancer

Volumn 98, Issue 3, 2011, Pages 277-290

  Dantzer, Françoise ^a   Noel, Georges ^b   Schreiber, Valérie ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b CENTRE PAUL STRAUSS   (France)

Author keywords

BRCA1 2; Chimio and radiosensitizers; Genome integrity; Poly(ADP ribose) polymerases inhibitors

Indexed keywords

NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NUCLEAR PROTEIN; POLY(ADENOSINE DIPHOSPHATE RIBOSE); ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RADIOSENSITIZING AGENT;

CANCER CELL; CANCER RADIOTHERAPY; CANCER THERAPY; CELL REGENERATION; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; EXCISION REPAIR; GENE MUTATION; HUMAN; NUCLEOTIDE METABOLISM; PROTEIN PROCESSING; REVIEW; SINGLE STRANDED DNA BREAK; BREAST TUMOR; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; NEOPLASM; PHYSIOLOGY; RADIATION DOSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DNA BREAKS; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; HUMANS; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS;

EID: 79955102726     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1330     Document Type: Review

References (38)

1. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 2006 ; 7 : 517-28. (Pubitemid 44036457)
2. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004 ; 26 : 882-93. (Pubitemid 39128102)
3. Ame JC, Rolli V, Schreiber V, et al. PARP-2. A novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 1999 ; 274 : 17860-8.
4. Boehler C, Gauthier LR, Mortusewicz O, et al. Poly(ADP-ribose polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc Natl Acad Sci 2011 ; 108 : 2783-8.
5. Kleine H, Luscher B. Learning how to read ADP-ribosylation. Cell 2009 ; 139 : 17-9.
6. Kleine H, Poreba E, Lesniewicz K, et al. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol Cell 2008 ; 32 : 57-69.
7. Dantzer F, de La Rubia G, Menissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry 2000 ; 39 : 7559-69. (Pubitemid 30422075)
8. Schreiber V, Ame JC, Dolle P, et al. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 2002 ; 277 : 23028-36. (Pubitemid 34967289)
9. Bryant HE, Petermann E, Schultz N, et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. Embo J 2009 ; 28 : 2601-15.
10. Haince JF, Kozlov S, Dawson VL, et al. Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J Biol Chem 2007 ; 282 : 16441-53. (Pubitemid 47100334)
11. Haince JF, McDonald D, Rodrigue A, et al. PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J Biol Chem 2008 ; 283 : 1197-208.
12. Sugimura K, Takebayashi S, Taguchi H, Takeda S, Okumura K. PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J Cell Biol 2008 ; 183 : 1203-12.
13. Audebert M, Salles B, Calsou P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J Biol Chem 2004 ; 279 : 55117-26. (Pubitemid 40066505)
14. Veuger SJ, Curtin NJ, Smith GC, Durkacz BW. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and theDNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 2004 ; 23 : 7322-9. (Pubitemid 39382135)
15. Wang M, Wu W, Rosidi B, Zhang L, Wang H, Iliakis G. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res 2006 ; 34 : 6170-82. (Pubitemid 44942738)
16. Menissier de Murcia J, Ricoul M, Tartier L, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. Embo J 2003 ; 22 : 2255-63. (Pubitemid 36565548)
17. Yelamos J, Schreiber V, Dantzer F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med 2008 ; 14 : 169-78.
18. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007 ; 13 : 1383-8. (Pubitemid 46450426)
19. Zaremba T, Curtin NJ. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med Chem 2007 ; 7 : 515-23. (Pubitemid 351836123)
20. Plummer R, Jones C, Middleton M, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor. AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008 ; 14 : 7917-23.
21. O'shaughnessy J, Osborne C, Pippen M, et al. Efficacy of BSI-201, a poly(ADP-ribose) polymerase-1(PARP-1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastasic triple-negative breast canacr (TNBC): results of a randomized Phase II trial. J Clin Oncol 2009 ; 27 : 3.
22. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005 ; 434 : 913-7. (Pubitemid 40559005)
23. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005 ; 434 : 917-21. (Pubitemid 40559006)
24. Patel AG, Sarkaria JN, Kaufmann SH. Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP- inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci 2011 ; 108 : 3406-11.
25. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009 ; 361 : 123-34.
26. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006 ; 66 : 8109-15. (Pubitemid 44299177)
27. Mendes-Pereira AM, Martin SA, Brough R, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009 ; 1 : 315-22.
28. Turner NC, Lord CJ, Iorns E, et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. Embo J 2008 ; 27 : 1368-77. (Pubitemid 351655175)
29. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 2005 ; 4 : 421-40. (Pubitemid 40704125)
30. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008 ; 14 : 312-23.
31. Reale A, Matteis GD, Galleazzi G, Zampieri M, Caiafa P. Modulation of DNMT1 activity by ADP-ribose polymers. Oncogene 2005 ; 24 : 13-9. (Pubitemid 40143860)
32. Caiafa P, Guastafierro T, Zampieri M. Epigenetics: poly(ADP-ribosyl) ation of PARP-1 regulates genomic methylation patterns. Faseb J 2009 ; 23 : 672-8.
33. Raval-Fernandes S, Kickhoefer VA, Kitchen C, Rome LH. Increased susceptibility of vault poly(ADP-ribose) polymerasedeficient mice to carcinogen-induced tumorigenesis. Cancer Res 2005 ; 65 : 8846-52. (Pubitemid 41377373)
34. Morrison C, Smith GC, Stingl L, Jackson SP, Wagner EF, Wang ZQ. Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis. Nat Genet 1997 ; 17 : 479-82. (Pubitemid 27518402)
35. Tong WM, Cortes U, Hande MP, et al. Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res 2002 ; 62 : 6990-6. (Pubitemid 35424091)
36. Tong WM, Ohgaki H, Huang H, Granier C, Kleihues P, Wang ZQ. Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice. Am J Pathol 2003 ; 162 : 343-52. (Pubitemid 36042016)
37. Aguiar RC, Yakushijin Y, Kharbanda S, Salgia R, Fletcher JA, Shipp MA. BAL is a novel risk-related gene in diffuse large B-cell lymphomas that enhances cellular migration. Blood 2000 ; 96 : 4328-34.
38. Cho SH, Goenka S, Henttinen T, et al. PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells. Blood 2009 ; 113 : 2416-25.